Artivion (NYSE:AORT) Earns Outperform Rating from Analysts at JMP Securities

Analysts at JMP Securities assumed coverage on shares of Artivion (NYSE:AORT) in a report issued on Wednesday, Briefing.com reports. The firm set an “outperform” rating and a $33.00 price target on the stock. JMP Securities’ target price points to a potential upside of 24.39% from the company’s previous close.

AORT has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. Oppenheimer upped their price objective on shares of Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Lake Street Capital boosted their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus raised their price target on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $30.60.

Artivion Stock Down 0.4 %

NYSE:AORT opened at $26.53 on Wednesday. The company’s 50-day simple moving average is $25.80 and its 200-day simple moving average is $24.58. The company has a debt-to-equity ratio of 1.07, a quick ratio of 4.04 and a current ratio of 5.63. Artivion has a fifty-two week low of $12.16 and a fifty-two week high of $29.24. The stock has a market capitalization of $1.11 billion, a P/E ratio of -110.54 and a beta of 1.74.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.04. The company had revenue of $98.02 million during the quarter, compared to analysts’ expectations of $97.70 million. Artivion had a negative net margin of 2.22% and a positive return on equity of 3.81%. On average, equities analysts anticipate that Artivion will post 0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Anthony B. Semedo sold 9,709 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the sale, the director now directly owns 34,159 shares of the company’s stock, valued at $853,633.41. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CAO Amy Horton sold 12,430 shares of Artivion stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $26.18, for a total transaction of $325,417.40. Following the completion of the transaction, the chief accounting officer now directly owns 139,989 shares in the company, valued at approximately $3,664,912.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Anthony B. Semedo sold 9,709 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $24.99, for a total value of $242,627.91. Following the completion of the transaction, the director now directly owns 34,159 shares of the company’s stock, valued at $853,633.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,109 shares of company stock worth $951,935. 8.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Artivion

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wasatch Advisors LP lifted its stake in shares of Artivion by 108.8% in the 1st quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after purchasing an additional 564,549 shares during the period. Perceptive Advisors LLC raised its position in shares of Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after acquiring an additional 124,725 shares during the period. First Eagle Investment Management LLC boosted its stake in shares of Artivion by 8.1% during the 1st quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock worth $12,066,000 after acquiring an additional 42,705 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Artivion by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after acquiring an additional 33,982 shares during the period. Finally, Creative Planning increased its stake in shares of Artivion by 182.1% in the 3rd quarter. Creative Planning now owns 28,635 shares of the company’s stock valued at $762,000 after purchasing an additional 18,486 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.